Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zimmer Biomet Holdings (ZBH – Research Report), Doximity (DOCS – Research Report) and Arvinas Holding Company (ARVN – Research Report).
Zimmer Biomet Holdings (ZBH)
Needham analyst Michael Matson maintained a Hold rating on Zimmer Biomet Holdings today. The company’s shares closed last Thursday at $121.23.
According to TipRanks.com, Matson has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Moderate Buy with an average price target of $136.43, implying a 12.7% upside from current levels. In a report issued on May 2, TD Cowen also maintained a Hold rating on the stock with a $143.00 price target.
See today’s best-performing stocks on TipRanks >>
Doximity (DOCS)
Morgan Stanley analyst Craig Hettenbach maintained a Sell rating on Doximity today and set a price target of $25.00. The company’s shares closed last Thursday at $23.74.
Hettenbach has an average return of
According to TipRanks.com, Hettenbach is ranked #928 out of 8864 analysts.
Doximity has an analyst consensus of Hold, with a price target consensus of $28.29.
Arvinas Holding Company (ARVN)
Barclays analyst Peter Lawson maintained a Buy rating on Arvinas Holding Company today and set a price target of $60.00. The company’s shares closed last Thursday at $32.11.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Arvinas Holding Company has an analyst consensus of Strong Buy, with a price target consensus of $65.25, a 92.6% upside from current levels. In a report issued on May 8, Wedbush also initiated coverage with a Buy rating on the stock with a $57.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZBH:
- Zimmer Biomet Enhances Governance and Employee Investment Plan
- Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024
- Zimmer Biomet price target lowered to $130 from $137 at Truist
- Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
- Zimmer Biomet backs FY24 adjusted EPS view $8.00-$8.15, consensus $8.06
